The ION Stent System incorporates a unique platinum chromium (PtCr) alloy designed specifically for coronary stenting and intended to improve the acute performance of coronary stent implantation in the treatment of coronary artery disease.
The ION Stent System features an innovative PtCr alloy and new stent design.
The thin-strut stent is designed for improved conformability, minimal recoil, and uniform lesion coverage and drug distribution.
The advanced low-profile delivery system facilitates precise delivery of the stent across challenging lesions.
Outside the US, including CE mark countries where it was approved in May 2010, the ION Stent System is commercialized as the TAXUS Element Paclitaxel-Eluting Coronary Stent System.
The stent has been evaluated in the PERSEUS trial, which reported 12-month results in March 2010, demonstrating positive safety and efficacy outcomes in workhorse lesions compared to the TAXUS Express2 Stent System.
Boston Scientific senior vice president and chief medical officer Keith Dawkins said the PERSEUS data confirmed that the proven TAXUS drug and polymer combination has been successfully transferred to the advanced ION Stent platform with excellent performance and comparable safety and efficacy.
